Brief: Precision BioSciences Announces Phase 1 Safety And Efficacy For Cohort 1, Lowest Dose Level In Eliminate-B, A First-In-Human Trial Of Pbgene-Hbv For Chronic Hepatitis B
06/08/2025 14:44
Aug 6 (Reuters) - Precision BioSciences Inc DTIL.O: PRECISION BIOSCIENCES ANNOUNCES PHASE 1 SAFETY AND EFFICACY FOR COHORT 1, LOWEST DOSE LEVEL IN ELIMINATE-B, A FIRST-IN-HUMAN TRIAL OF PBGENE-HBV FOR CHRONIC HEPATITIS B PRECISION BIOSCIENCES INC - COHORT 1 ESTABLISHED SAFE AND WELL-TOLERATED PROFILE PRECISION BIOSCIENCES INC - EXTENDED CASH RUNWAY TO SECOND HALF OF 2027 PRECISION BIOSCIENCES INC - PBGENE-HBV SHOWED 47-69% HBSAG REDUCTION Source text: ID:nBw4Hxcvla Further company coverage: DTIL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Precision Biosciences
See all newsPrecision BioSciences Inc reports results for the quarter ended June 30 - Earnings Summary
Precision BioSciences Q2 net loss widens on warrant liability charge
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Brief: Precision Biosciences - Enters First Amendment To Loan And Security Agreement With Banc Of California - SEC Filing